OptimizeRx Corporation · NASDAQ:OPRX
OptimizeRx — Marcum Conference 2015
29 slides from OptimizeRx's conference presentation, May 2015
Slide 1: May 2015 Marcum Conference
May 2015 Marcum Conference David Harrell, CEO Doug Baker, CFO (OTCQB: OPRX)
Slide 2: Safe Harbor
SAFE HARBOR : This presentation contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The word
Slide 3: Major Changes in Market
Major Changes in Market Cant directly Drug samples Technology & govt Patient not filling Rxs promote to are becoming is pushing less due to rising out o docs like they banned expensive therapies pocket copay costs used to Traded under OPRx (OTCQB)
Slide 4: Pharma wastes $1-1.5 billion annually on infeasible calls
90% only 80% 20% get to actually speak to the doctor! 70% 60% 2008 2009 2010 2011 2012 And decreased accessibility often means unproductive calls… Pharmaceutical companies waste between $1˗˗$1.5 billion annuallyon infeasible calls Source: AccessMonitor™. Traded under OPRx (OTCQB)
Slide 5: $4B samples market shifting to effective patient support
The $4B samples market is shifting to other areas of more effective patient support … Including free trial vouchers & copay discounts Traded under OPRx (OTCQB)
Slide 6: Physician EHR adoption and ePrescribing
80% Office-based physicians using an EHR in 2013 85% Now ePrescribing Notes: EHR is electronic health record. “Any EHR system” is a medical or health record system that is either all or partially electronic (excluding systems soley for billing). Data for 2001-2007 are from in-person National Ambulat
Slide 7: ePrescribing Projected Growth
ePrescribing Projected Growth 2 billion 2 billion By 2016, an estimated Prescription Renewal Responses New Prescriptions 2 billion prescriptions will be 1 billion electronically sent per year 57 million and growing thereafter. 750 million 269 million 75% 96 million 500 million 474 million 400 millio
Slide 8: Copay costs continue to go up for branded meds
Co Pay COSE continue to go up for branded meds Average Copayments by Prescription Drug Tier, 2002 vs. 2014 = 2002 = 2014 $83 $53 $31 $32 $18 | TL | ! na First-Tier Drugs Second-Tier Drugs Third-Tier Drugs Fourth-Tier Drugs (Generic) (Preferred) (Nonpreferred) Source: Pembroke Consulting analysis of
Slide 9: OptimizeRx is targeting most valued pharma offering by doctors
OptimizeRx is targeting FF most valued pharma offering by doctors: VIEW GENERAL FOLLOWING PRACTICE AS ENDOCRINOLOGY/ | AND FAMILY | INTERNAL IMPORTANT | CARDIOLOGY | DIABETOLOGY PRACTICE MEDICINE | NEUROLOGY | ONCOLOGY | PEDIATRICS | PSYCHIATRY | UROLOGY 83% Vouchers or 82% 82% 85% 80% 73% 74% 82% 7
Slide 10: SampleMD: flagship SaaS product
SampleMD: OptimizeRx’s flagship SaaS product displays sample vouchers and copay coupons to doctors automatically and is paid by the pharmaceutical manufacture each time a coupon or voucher is electronically sent with the ePrescription to the pharmacy. EHR sends electronic request to SampleMD when do
Slide 11: Doctor Selects Medication and Dose
Doctor Selects Medication and Dose
Slide 12: OPRx Instantly returns eligible patient support
OPRx Instantly returns eligible patient support for doctor to review and send to pharmacy with prescription
Slide 13: Offer displayed for printing and sent to pharmacy
After ePrescription is sent with offer, full support offer is displayed for printing to patient and is sent to pharmacy.
Slide 14: Our clients are the leading pharmaceutical companies
Our clients are the Leading pharmaceutical COMPANIES inthe worta Ub NOVARTIS ~ eo, AstraZeneca 2 y) SANOFI Pfizer) BS Genentech BAYER Ee R €® Bristol-Myers Squibb Lilt, Abbott A Promise for Life tact Diagnostics Watson : “Wrastellas ow) y Dalich-Sankyo novo nordisk” P auxiuium | AAMARIN CO tamer, SS
Slide 15: Reaching over 250,000 healthcare providers
by reaching over 250,000 healthcare providers, thus owning the largest available promotional point of prescribe network in the industry
Slide 16: High ROI on increasing ePrescriptions for clients
OptimizeRx is confirming high ROI on increasing ePrescriptions For our clients THE INDEPENDENT ANALYSIS SHOW! RETURN ON INVESTMENT (RON BASED SOLELY PRESCRIPTIONS GENERATED FROM THE AWARENESS OF FINANCIAL SUPPORT AT POINT: Optimize.
Slide 17: Efficiently supports and benefits all key stakeholders
Efficiently supports & benefits all key stakeholders! • Pharma: Provides promotional access to prescribers and patients at the point of prescription • Doctors: Provides information regarding drugs and the financial assistance available to patients, allowing doctors to choose their preferred drug whi
Slide 18: SampleMD Standard Revenue Metrics
Set Up Fee: $25K SampleMD Standard Revenue Metrics Reporting: $2K/mth. Cost Per Coupon Distribution: NOTE: We do have Enterprise Wide discounts to incentivize $5.00 Manufacturers to add portfolio of products to drive increased volume Traded under OPRx (OTCQB)
Slide 19: 2 Billion ePrescriptions estimated in 2016
2 Billion ePrescriptions estimated in 2016 Industry report conservatively made the following assumptions: • 100M in prescriptions associated with coupons in 2010 or 11% of brand prescriptions • Co-pay coupons to increase 15% per year to 500M in 2021 Source: Source: 4. Cleveland Resource Company 5. P
Slide 20: $20 million in transactional fees
$20 million dollars in transactional fees* Generating Net Income of $5.5 Million Our business is highly leveraged opportunity due to fix costs not required to escalate with revenue growth. Estimated at 4 million transactions @ $5 per Traded under OPRx (OTCQB)
Slide 21: Growth drivers: physician utilization, platforms, pharma budgets
Grow physician Grow Grow Pharma utilization in physician Brands, current utilization in Programs & EHR new platforms Budgets Network Traded under OPRx (OTCQB)
Slide 22: Transactions formula: doctors x promoted brands
# of doctors # of promoted in our networks x brands prescribed in network = # of transactions Traded under OPRx (OTCQB)
Slide 23: Expanded Piggy-back Solutions
Expanded Piggy-back Solutions provide Fu rther promotional revenue opportunities PATIENT EDUCATION Provide customized patient education materials that can be printed EHR BRAND MESSAGING Deliver targeted product messaging when your brand or therapeutic during the e-prescribs process category is being
Slide 24: U.S. pet medications reached over $8 Billion
In U.S., Pet medications reached over $8 Billion
Slide 25: WPP at a glance
WPP at a glance: WPP is the world leader In marketing communications services. Employees: 170,000 Offices: 3000 Countries: 110 Revenues: £10.4bn
Slide 26: Revenue growth 2011-2014
2014 Revenue $6.5million 2013 Revenue $4.7 2012 Revenue $2.05 2011 Revenue $1.1 1Q 2Q 3Q 4Q* Traded under OPRx (OTCQB)
Slide 27: Q1 2015 highlights
• Q1 2015 Sales increased 15% over 2014 first quarter • Positive cash flow from operations of $87K in Q1 • Strong cash balance - in excess of $3.5 million • Launched within Practice Fusion EMR in April • Received commitment to begin running key campaigns through NextGen, anticipated to start in June
Slide 28: Huge Market, Huge Benefits to all
Proven proprietary technology Low fixed overhead Huge Benefits Huge Market successfully SaaS model that to all implemented into offers high leveraged Stakeholders largest promotional financial opportunity eRx network 2 Billion eRx Beginning stages of helping Infinitely scalable Technology and suppor
Slide 29: Contact details
dharrell@optimizerx.com dbaker@optimizerx.com 248.651.6568, ext 807